In clinical practice, we recommend to perform panel or exome sequencing of tumor biopsies at initial diagnosis to determine potentially actionable gene mutations and fusions (including BRAF, FGFR, IDH1, IDH2, BRCA1, BRCA2, and NTRK) for further lines of therapy. This evidence concerns the gene BRAF and neoplasm.